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Abstract
Background: The orphan nuclear receptor estrogen-related receptor a (ERRa) is a member of the nuclear receptor
superfamily. It was identified through a search for genes encoding proteins related to estrogen receptor a (ERa). An
endogenous ligand has not been found. Novel ERRa antagonists that are highly specific for binding to the ligand binding
domain (LBD) of ERRa have been recently reported. Research suggests that ERRa may be a novel drug target to treat breast
cancer and/or metabolic disorders and this has led to an effort to characterize the mechanisms of action of N-[(2Z)-3-(4,5-
dihydro-1,3-thiazol-2-yl)-1,3-thiazolidin-2-yl idene]-5H dibenzo[a,d][7]annulen-5-amine, a novel ERRa specific antagonist.
Methodology/Principal Findings: We demonstrate this ERRa ligand inhibits ERRa transcriptional activity in MCF-7 cells by
luciferase assay but does not affect mRNA levels measured by real-time RT-PCR. Also, ERa (ESR1) mRNA levels were not
affected upon treatment with the ERRa antagonist, but other ERRa (ESRRA) target genes such as pS2 (TFF1), osteopontin
(SPP1), and aromatase (CYP19A1) mRNA levels decreased. In vitro, the ERRa antagonist prevents the constitutive interaction
between ERRa and nuclear receptor coactivators. Furthermore, we use Western blots to demonstrate ERRa protein
degradation via the ubiquitin proteasome pathway is increased by the ERRa-subtype specific antagonist. We demonstrate
by chromatin immunoprecipitation (ChIP) that the interaction between ACADM, ESRRA, and TFF1 endogenous gene
promoters and ERRa protein is decreased when cells are treated with the ligand. Knocking-down ERRa (shRNA) led to similar
genomic effects seen when MCF-7 cells were treated with our ERRa antagonist.
Conclusions/Significance: We report the mechanism of action of a novel ERRa specific antagonist that inhibits
transcriptional activity of ERRa, disrupts the constitutive interaction between ERRa and nuclear coactivators, and induces
proteasome-dependent ERRa protein degradation. Additionally, we confirmed that knocking-down ERRa lead to similar
genomic effects demonstrated in vitro when treated with the ERRa specific antagonist.
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Introduction
ERRa is an orphan member of the superfamily of hormone
nuclear receptors. The ERR subfamily consists of three members,
ERRa, ERRb, and ERRc. ERRa was one of the first orphan
receptors identified. It was found by using the DNA-binding
domain (DBD) of Estrogen Receptor a (ERa) as a hybridization
probe to screen recombinant DNA libraries [1]. Amino acid
sequence comparison shows that apart from ERRb and ERRc,
ERRa is more closely related to ERa and ERb than any other
member of the superfamily of nuclear hormone receptors. ERRa
and both ERa and ERb DNA Binding Domains share 70% amino
acid identity. ERRa and ERa Ligand Binding Domains (LBD)
share 36% amino acid identity; while ERRa and ERb LBD’s
share 37% amino acid identity [2,3]. In addition, although ERs
and ERRs share a number of similar biochemical properties,
ERRs do not bind 17b-estradiol (E2).
ERRa is known to bind to DNA as either a monomer or a
dimer. ERRa can bind to estrogen-response elements (ERE)
containing the recognition motif AGGTCAnnnTGACCT; ERRa
also recognizes the single consensus half-site sequence
TNAAGGTCA, referred to as an ERR-response element (ERRE)
[4]. ERRa can bind the inverted repeat ERE as a dimer [5]. The
binding of ERRa to an ERE or ERRE can lead to either a
stimulatory or repressive event depending on the cell type,
response element, context within a specific promoter, phosphor-
ylation state of the receptor, potential ligands present, genomic
context of ERRa (either competing or cooperating with ERa for
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transcription factors involved [2]. Consequently, ERRs and ERs
share common target genes (such as pS2, lactoferrin, and
osteopontin) and exhibit cross-talk [6,7,8,9].
Whereas many other members of the steroid receptor
superfamily are activated by ligand (including ERs), ERRs are
constitutively active without the addition of a specific ligand.
ERRa and ERRb have been shown to be constitutive activators of
the classic ERE [10]. The authors also demonstrate that the p160
cofactors AIB1 (also known as SRC-3, NCoA3, ACTR, RAC3),
GRIP1 (also known as SRC-2, NCoA2, TIF2) and SRC-1 (also
known as NCoA1) potentiate the transcriptional activity by ERRa.
It has been reported [9,10] using glutathione S-transferase (GST)
pull down assays that ACTR (AIB1), SRC-1, and GRIP1 interact
with the AF-2 domain of the LBD of ERRa without the addition
of exogenous ligand. Moreover, fluorescence resonance energy
transfer (FRET) assay has been used to demonstrate that SRC-1
and SRC-2 (GRIP-1) interact with all three ERRs without the
addition of exogenous ligand. While ligands are not required for
activation of ERR activity, there are known ligands which can
modulate ERRs. Diethylstilbestrol (DES) antagonizes all three
ERR isoforms whereas 4-hydroxytamoxifen (4-OHT) is an
isoform specific inhibitor of ERRb and ERRc [11,12,13].
In addition to the p160 family of nuclear receptor coactivators
that modulate ERR activity, another class of coactivators has also
been reported. This class is made up of Proliferator-activated
Receptor c Coactivator-1 a (PGC-1a) [14,15,16,17] and Prolif-
erator-activated Receptor c Coactivator-1 b (PGC-1b) [18]. PGC-
1a and PGC-1b are important regulators of genes that control
many key aspects of metabolism including glucose uptake,
gluconeogenesis, mitochondrial biogenesis, adipocyte cell fate
specification, and adaptive thermogenesis [19]. PGC-1a interacts
withERRa and potentiatesitstranscriptionalactivity[14,15,16,17].
In a direct comparison of the binding affinities of SRC-1 and PGC-
1atobindERRa,ithasbeenshownthat ERRabindsPGC-1a with
140-fold increased affinity in comparison to SRC-1 [20].
We have previously reported ERRa-subtype selective antagonist
ligands [21]. Other known ERRa ligands include the synthetic
estrogen DES [13] and the ERRa selective inverse agonist,
XCT790 [22]. It has been established that XCT790 induces
ubiquitin proteasome dependent ERRa degradation [23]. An
additional inverse agonist, Cyclohexylmethyl-(1-p-tolyl-1H-indol-3-
ylmethyl)-amine, has been co-crystallized with the human ERRa
LBD and the authors describe a novel molecular mechanism of
action for inverse agonism of ERRa [24]. Moreover, it is known
that theselectiveestrogen receptormodulator(SERM)4-OHTis an
antagonist to ERRb and ERRc in FRET and cell-based reporter
assays [11,12]. Over the past several years the scientific literature
has continued to suggest that the orphan nuclear receptor ERRa
could represent an important target for the treatment of breast
cancer [2,3,25]. Novel ERRa-subtype specific antagonists that are
highly specific for the ligand binding domain (LBD) of ERRa have
been recently reported [21]. The possible important use for these
ligands has led to an effort to study mechanisms of action of ERRa
antagonists. In particular, N-[(2Z)-3-(4,5-dihydro-1,3-thiazol-2-yl)-
1,3-thiazolidin-2-yl idene]-5H dibenzo[a,d][7]annulen-5-amine,
which has a strong antagonistic effect on the constitutive interaction
between ERRa and nuclear coactivators was identified [21]. For
simplicity,inthepresentstudyN-[(2Z)-3-(4,5-dihydro-1,3-thiazol-2-
yl)-1,3-thiazolidin-2-yl idene]-5H dibenzo[a,d][7]annulen-5-amine
will be called ‘‘Compound A’’.
Our studies demonstrate that Compound A antagonizes ERRa
transcriptional activity but shows little affect on ERRa mRNA
levels. ERa mRNA and protein levels were not affected upon
treatment with the ERRa antagonist, but other ERRa target
genes such as pS2, osteopontin, and aromatase mRNA levels
decreased upon treatment with the ERRa-subtype specific ligand.
In addition, this ERRa tri-cyclic ligand antagonizes the constitu-
tive interaction between ERRa and nuclear coactivators. We
provide evidence that ERRa protein degradation is induced by the
ERRa-subtype specific antagonist and this degradation is
mediated though the ubiquitin 26S proteasome pathway. We
report that the interactions between ERRa protein and the
endogenous ERRa responsive gene promoters (ESRRA, ACADM
and TFF1) are decreased by treatment with Compound A. Lastly,
knocking-down ERRa by shRNA led to similar genomic effects
seen when MCF-7 cells were treated with our ERRa antagonist.
Materials and Methods
Cell Lines and Reagents
The MCF-7 cell line (obtained from ATCC, Manassas, VA),
and MCF-7/shRNA ERRa RNAi cell lines were maintained in
EMEM with Earle’s BSS and 2 mM L-glutamine that was
modified to contain 1.0 mM sodium pyruvate, 0.1 mM nonessen-
tial amino acids, and 1.5 g/L sodium bicarbonate. It was also
supplemented with 10% fetal bovine serum, 10 ug/ml bovine
insulin, 100 units/ml of penicillin/streptomycin, at 37uC and 5%
CO2. All cell lines were determined to be free of mycoplasma.
Experiments that required maintenance of cells in ‘‘stripped
media,’’ were washed with phosphate buffered saline, and then the
media was changed to EMEM without phenol red that contained
10% charcoal dextran – treated FBS (CD-FBS).
Transient Transfection and Luciferase Assay
MCF-7 cells were maintained in phenol free EMEM/CD-FBS
media for 4 days prior to performing transfections. 25,000 cells per
well were plated into 96-well plates. 0.125 ug pGL2 Luc
(Promega), or 0.125 ug p3xERE-TK-LUC [pGL2 plasmid
(Promega, Madison, WI) containing 3 tandem repeats of the
estrogen response element (ERE) sequence 59 – TTTGAT-
CAGGTCACTGTGACCTCTAGAGT-39, placed upstream of
a minimal herpes simplex thymidine kinase (TK) promoter
directing the expression of the luciferase coding sequence (a
generous gift from Tina Chang, Merck Research Laboratories,
Rahway, NJ) and 0.0125 ug of phRL-TK renilla plasmid
(Promega) were co-transfected in triplicate wells along with (when
indicated) either 0.0625 ug pcDNA 3.1 (Invitrogen, Carlsbad, CA)
or 0.0625 ug pcDNA3.1 hERRa (described below). Plasmids were
diluted in OptiMEM (Invitrogen), the transfection reagent
Lipofectamine LTX (Invitrogen) was added to the DNA solution
and incubated for 25 minutes at room temperature. Next, the
DNA-Lipofectamine complexes were added to the cells and
incubated overnight. Subsequently, the cells (in triplicate) were
treated with vehicle (DMSO), 100 pM 17-beta-estradiol (Sigma),
5 uM Compound A (Merck & Co, West Point, PA), 100 pM 17-
beta-estradiol/5 uM Compound A, or 1 uM ICI-182,780 (faslo-
dex) (Tocris, Ellisville, MO) for 48 hours. Cells were then
harvested and cell lysates were assayed for luciferase activity
(renilla normalized) as per the manufacturer’s directions by
utilizing the Dual-Luciferase Reporter Assay System (Promega)
and the Wallac Victor plate reader (Perkin Elmer, Wellesley, MA).
Real-time RT-PCR
MCF-7 cells were maintained in phenol free EMEM/CD-FBS
media for 4 days prior to drug treatments (in triplicate) and MCF-
7/shRNA ERRa RNAi cells were maintained in normal media
containing whole serum (described above). Total RNA was
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or 5 uM Compound A for 24 or 48 hours. The RNA samples
were DNase I (Ambion Inc., Austin, TX) treated and cDNA was
synthesized (High-Capacity cDNA Archive Kit, Applied Biosys-
tems). Real-time RT-PCR was performed with an ABI 7900 HT
sequence detection system (Applied Biosystems, Foster City, CA).
Primer/probe sets for target genes: human ERRa (ESRRA)
(Hs00607062_gH), human ERa (ESR1) (Hs00174860_m1), hu-
man PGC-1a (PPARGC1A) (Hs00173304_m1), human PDK4
(PDK4) (Hs00176875_m1), human osteopontin (SPP1)
(Hs00959010_m1), human pS2 (TFF1) (Hs00170216_m1), human
ACADM (ACADM) (Hs00163494_m1) and 18S rRNA endoge-
nous control (4308329) were purchased from Applied Biosystems.
The housekeeping gene18S rRNA was used as the internal
quantitative control for normalization. Relative gene expression
was calculated with the DDCt method as outlined in the Applied
Biosystems User Guide. In brief, the threshold cycle (CT) values for
the target gene and reference (18S) were determined by ABI
PRISM Sequence Detection System software. Mean CT values
and standard deviations were calculated in Microsoft Excel. DCT
was calculated by DCT=C T target2CT reference. After the mean
and standard deviation of the DCT’s value were determined,
DDCT=DCT test sample2DCT calibrator sample. Next, the
standard deviations of the DDCT values were calculated and
finally, the fold-differences were determined by the DDCT,
expressed as 2
2DDCT.
Expression, Purification, and Biotinylation of Fusion
Proteins
Bacterial expression plasmid constructs GST-AIB1 RID, GST-
GRIP-1RID,GST-PGC-1aRIDalongwithbacterialgrowth,fusion
protein expression, purification, cleavage of GST, and biotinylation
of AIB1, GRIP-1, and PGC-1a have been previously described [21].
ERRa and ERa Expression Plasmids
For construction of the pcDNA3.1 hERRa expression plasmid,
full-length human ERRa was amplified from human brain
Marathon-ready cDNA (Clonetech Laboratories Inc.) by using
forward primer 59-GGGAAGCTTAGGTGACCAGCGCCAT-
GTCCAGCCAGG-39,r e v e r s ep r i m e r5 9- GGGGAATTCAC-
CCCTTGCCTCAGTCCATCATGGCCTCG-39,a n dc l o n e di n t o
mammalian expression vector pcDNA3.1(+)( I n v i t r o g e n )( G e n e r o u s
gift from Dr. Sheng-Jian Cai, Merck Research Laboratories,
Rahway, NJ). For the pcDNA3.1 hERa expression plasmid, the
full-length human ERa was amplified from human liver cDNA
(amino acids 1–595) and initially cloned into the BamH1 and SpeI
sites in the phagemid vector pBlueScript KS (-) (Stratagene, La Jolla,
CA). Subsequently, full-length human ERa (a.a. 1–595) was
subcloned as an EcoRV – SpeI fragment into EcoRV – XbaI sites
of the mammalian expression vector pcDNA3.1(+)( I n v i t r o g e n ,
Carlsbad, CA).
ERRa Antibody
The ERRa specific peptide sequence: AGPLAVAGGPRK-
TAAPVN, was synthesized by EvoQuest Custom Antibody
Services (Invitrogen). The peptide was then coupled to a hapten
carrier (keyhole limpet hemocyanin) for immunization. Polyclonal
antibodies were generated in New Zealand white rabbits and the
polyclonal ERRa specific antibody (pAb ERRa) was purified by
affinity chromatography.
In Vitro Expression of ERa and ERRa
Full-length human ERa (pcDNA3.1 hERa) and full-length
human ERRa (pcDNA3.1 hERRa) proteins were expressed by a
TnT coupled reticulocyte lysate system as per the manufacturer’s
recommended conditions (Promega Corporation) for use as positive
controls with Western Blotting. In addition, [
35S]methionine was
added to the transcription/translation reaction for radiolabeled
hERRa that was used in the biotinylated pull-down assays.
Biotinylated Pull-down Assay
ProFound Pull-Down Biotinylated Protein:Protein Interaction
Kit (Pierce, Rockford, IL) was utilized and manufacture’s
instructions were followed. Briefly, streptavidin beaded agarose
(washed with 16TBS) was incubated with biotinylated protein in
16TBS at 4uC in provided spin column for 1 hour on a rocking
platform and then columns were centrifuged. Biotin blocking
solution was added, samples were incubated and centrifuged.
Biotin blocking step was repeated once followed by washes with
16 TBS. In vitro translated [
35S]-labeled protein in 16 TBS was
added along with DMSO (control), 10 mM Compound A, or
10 mM DES to biotinylated protein bound to streptavidin beaded
agarose. The samples were then incubated for 4 hours at 4uCo na
rocking platform. The bound protein was washed with 16 TBS
and the beads were collected by centrifugation. The bound protein
was eluted in SDS sample buffer, loaded into a 10% NuPage Bis-
Tris Gel (Invitrogen) and analyzed by phosphorimaging (Typhoon
9400, ImageQuant TL software, GE Healthcare). Positive control,
10% input, in vitro translated full-length human ERRa [
35S]-
labeled protein. Negative control, sulfo-NHS-LC-biotin pulled
down with streptavidin beaded agarose and incubated with ERRa
[
35S]-labeled protein. Equal loading was determined by staining
10% NuPage Bis-Tris Gels with Coomassie brilliant blue stain.
Chromatin Immunoprecipitation (ChIP) Assay
After 4 days of growing the MCF-7 cells in EMEM without
phenol red that contained 10% CD-FBS, the cells were treated
with DMSO or 5 uM Compound A in duplicate for 24 and
48 hours. Subsequently, the cells were fixed according to
Genpathway, Inc. cell fixation protocol which can be found at
www.genpathway.com and the chromatin immunoprecipitation
were carried as described (43) except ERRa antibody (described
above) or GRIP-1 (Santa Cruz Biotechnology, M-343) were used
for the immunoprecipitation. Primers used for quantitative real-
time PCR (Q-PCR) were as follows: ERRa forward, 59 – CTT
CCC CGT GAC CTT CAT T – 39, ERRa reverse, 59 – AGC
CGA CTT AAA ACA TGC AAT A – 39; ACADM forward, 59 –
AAC GCA GAA AAC CAA ACC AG – 39, ACADM reverse, 59 –
CAT GCT CCG TGA CCC TTG; pS2 forward, 59 – ACA TGG
AAG GAT TTG CTG ATA – 39, pS2 reverse, 59 – TTC CGG
CCA TCT CTC ACT AT – 39, and Untr12 forward, 59 – TGG
ACC TTT ACC TGC TTT ATC A – 39 and reverse, 59 – AGC
AAG GAC TAG GAT GAC AGA A – 39. All Q-PCR
amplifications were performed in triplicate.
Analysis of ERa and ERRa Protein Levels
MCF-7 cells were grown in phenol free EMEM/CD-FBS media
for 4 days prior to drug treatments and MCF-7/shRNA ERRa
RNAi cells were maintained in normal media containing whole
serum (described above). MCF-7 cells were treated with vehicle
(DMSO), 10 nM 17-beta-Estradiol (Sigma), 10 nM 4-hydroxyta-
moxifen (Sigma), 10 nM ICI-182,780 (Tocris), or 5 uM Com-
pound A (Merck & Co., West Point, PA) for 12, 24, or 48 hours.
Nuclear protein extractions were carried out according to the
protocol of the NE-PER Nuclear Extraction Kit (Pierce). For the
protein degradation assay MCF-7 cells were treated with vehicle
(DMSO), 5 uM Compound A, 1 uM MG132 (Sigma), or 5 uM
Compound A/1 uM MG132 for 36 hours. RIPA buffer (Pierce)
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manufacturer’s protocol. Protein concentration was determined
with the DC Protein Assay (Bio-Rad, Hercules, CA) and 20 ug of
nuclear protein extracts or 40 ug of whole cell protein extracts
were loaded into a 10% NuPage Bis-Tris Gel (Invitrogen). After
electrophoresis, the proteins were transferred to nitrocellulose
membrane (Invitrogen). Western blotting was carried out by
utilizing pAb ERRa (described above) or ERa (G-20, Santa Cruz
Biotechnology, Santa Cruz, CA), ECL rabbit IgG, HRP-linked
whole antibody (from donkey) (GE Healthcare, Piscataway, NJ),
and Western Lightning Chemiluminescence Reagent Plus (Perkin
Elmer, Boston, MA). Equal loading of nuclear protein extracts per
lane was assessed by Coomassie Brilliant Blue staining of a gel run
in parallel while equal loading of whole cell protein extracts per
lane was assessed by stripping the nitrocellulose membrane and re-
probing with b-actin monoclonal antibody (Sigma). Densitometric
quantification of protein levels from three independent experi-
ments were performed by using the AlphaEase FC Imaging
Software program (Alpha Innotech, San Leandro, CA). MCF-7/
shRNA ERRa RNAi cell line nuclear protein extraction, protein
concentration determination, electrophoresis, protein transfer, and
Western blotting are described above.
Stable Transfection with shRNA ERRa and shRNA (-)
Plasmids
0.5 ug of four unique SureSilencing shRNA plasmids (Super-
Array Bioscience Corporation, Frederick, MD) specific for human
ERRa and a negative control were transfected separately into
40,000 MCF-7 cells per well (24-well plate). shRNA (-) and shRNA
ERRa plasmidswereunderthecontrolofthe U1promoterand also
contain GFP. Plasmids were diluted in OptiMEM (Invitrogen), the
transfection reagent Lipofectamine LTX (Invitrogen) was added to
the DNA solution and incubated for 25 minutes at room
temperature. Next, the DNA-Lipofectamine complexes were added
to the cells, incubated for 24 hours, and then cells were replenished
with fresh media. Subsequently, transfected cells were expanded.
FACS Sorting of MCF-7/shRNA ERRa RNAi Cells
Cells were resuspended in DPBS (Gibco 14190), 0.1% BSA,
25 mM HEPES; GFP-enriched cells were sorted on a FACSVan-
tage-SE flow cytometer (Becton Dickinson, San Jose, CA)
equipped with an Innova 70C-4 (488 nm) argon ion laser
(Coherent, Palo Alto, CA). GFP was excited at 488 nm and
fluorescence emission was detected using a 530/30 BP filter. Data
from the experiments were analyzed with CellQuest software
(Becton Dickinson). GFP expressing cells underwent 4 rounds of
GFP enrichment by FACS. Extent of ERRa knock-down was
measured in triplicate by real-time RT-PCR (described above).
Statistics
Error bars represent standard error of the mean (SEM) between
replicates of a given experiment. Comparisons between two groups
were made by analysis of variance (ANOVA) followed by a student
t-test at 0.05 significance level with P values indicated.
Results
Compound A Inhibits Constitutive Transcriptional
Activity of ERRa
ERRa binding to ERE’s and subsequent constitutive transacti-
vation has been shown [10,13,26]. In addition, Kraus et al [26]
has reported that ERRa can modulate estrogen responsiveness
and effectively compete with ERa for the binding to EREs. To test
whether our novel ERRa ligand antagonizes the constitutive
transcriptional activity of ERRa, we cotransfected MCF-7 breast
cancer cells with the reporter plasmid p3xERE-TK-Luc or the
ERE-negative control plasmid (pGL2 Luc) together with the
control parental vector pcDNA3.1 and phRL-TK renilla plasmid
for normalization. The co-transfected cells were then treated with
vehicle (DMSO), 100 pM E2, 5 uM Compound A, 100 pM E2/
5 uM Compound A, or 1 uM ICI - 182,780. After 48 hours cells
were harvested and cell lysates were assayed for luciferase activity.
Cells transfected with the p3xERE-TK-Luc and treated with
DMSO demonstrated constitutive (basal level) activity with a 73-
fold increase in transcriptional activity above cells transfected with
pGL2 Luc and treated with DMSO (Fig. 1A). MCF-7 cells
transfected with the p3xERE-TK-Luc and treated with E2 had a
6.3-fold increase in transcriptional activity verses the basal level.
Cells treated with the ERRa antagonist, Compound A are
transcriptionally repressed, 0.73-fold (or 27% decrease) below
basal level (P=0.032) (Fig. 1A inset).
To study the effect of the ERRa-subtype specific antagonist on
estrogen dependent transcriptional activity, cells were treated with
E2 in combination with the ERRa antagonist (Fig. 1A). When cells
were treated with estrogen plus Compound A there was a
reduction in transcriptional activation. Additionally, the estrogen
receptor selective antagonist, ICI - 182,780, greatly reduces any
transactivation suggesting that ER is needed for estrogen
stimulated expression to occur at the ERE (Fig. 1A). Thus, taken
together, the functionality of the interconnections/cross-talk of
ERRa and ERa at an ERE is illustrated.
Would having more ERRa present lead to greater antagonism
by Compound A? To answer this question, a similar co-
transfection experiment described above was performed and the
ERRa expression plasmid (pcDNA3.1 hERRa) was co-transfected
(instead of control parental vector pcDNA3.1) with either
p3xERE-TK-Luc or pGL2 Luc. Over-expressing ERRa in
MCF-7 cells leads to decreased down modulation within all
treatment groups relative to luciferase activity (compare Fig. 1A to
1B). Cells transfected with the p3xERE-TK-Luc+pcDNA 3.1
hERRa demonstrated constitutive (basal level) activity by
conferring an 114-fold increase in transcriptional activity above
cells transfected with pGL2 Luc and treated with vehicle (Fig. 1B).
MCF-7 cells transfected with the p3xERE-TK-Luc+pcDNA 3.1
hERRa and treated with 100 pM E2 conferred a 2.6-fold increase
in transcriptional activity verses the basal level. Moreover, while
treating cells with 5 uM Compound A lead to a 27% decrease
below the basal constitutive activity in the original experiment
(Fig. 1A); over expressing ERRa leads to a 45% decrease in
transactivation upon treatment with 5 uM Compound A
(P=0.001) (Fig. 1B inset). Similarly, 5 uM Compound A plus
100 pM E2 also led to a 33% decrease. Therefore, while
transfecting ERRa into MCF-7 cells leads to an overall decreased
modulation of estrogen responsiveness (also previously reported
[26]), a larger window of antagonism was also demonstrated with
more ERRa present. Over expressing ERRa in MCF-7 cells
nearly abolishes transactivation upon treatment with 1 uM ICI
182,780 (Fig. 1B).
Compound A Suppresses Expression of ERRa Target
Genes
Since Compound A was shown to inhibit the constitutive
transcriptional activity of ERRa (Fig. 1), we next wanted to
examine the effects of Compound A on target gene expression at
the mRNA level. Quantitative real-time RT-PCR was used to
measure ERRa (ESRRA) target gene mRNA levels in MCF-7 cell
treated with 5 uM Compound A for either 24 or 48 hours. No
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measured after 24 and 48 hours of treatment with the ligand
(Fig. 2, S1). On the contrary, other known ERRa target genes
including medium-chain acyl coenzyme (ACADM) [4], aromatase
(CYP19A1) [27], pyruvate dehydrogenase kinase 4 (PDK4) [28],
osteopontin (SPP1) [7], and pS2 (TFF1) [6] were all down
modulated upon treatment with the compound for 48 hours
(Fig. 2, S1). Additionally, peroxisome proliferator-activated
receptor coactivator-1a (PGC-1a)( PPARGC1A), although not
considered an ERRa target gene, is known to bind and interact
with ERRa [14,29], was robustly down modulated upon treatment
with the ERRa antagonist in comparison to cells treated with
vehicle alone (Fig. 2, S1).
Compound A Decreased Constitutive Interactions of
ERRa with Nuclear Coactivators AIB1, GRIP-1 and PGC-1a
Our group has previously reported an IC50 of 170 nM for
Compound A in an ERRa LBD/PGC-1a coactivator homoge-
nous time-resolved fluorescence interaction assay [21]. To further
study this inhibitory effect we performed biotinylated pull-down
assays with AIB1, GRIP-1, and PGC-1a nuclear coactivators to
look at the effects of Compound A on ERRa/nuclear coactivator
constitutive interaction. The receptor interaction domains (RID) of
AIB1 (aa 557–773), GRIP-1 (aa 565–798), and PGC-1a (aa 1–338)
were expressed, biotinylated, and purified. Full-length human
ERRa protein was expressed and
35S[methionine] labeled. After
incubating ERRa, nuclear coactivator, and 10 uM ligand, a
standard streptavidin bead/biotinylated pull-down assay was
carried out (see Materials and Methods). The constitutive
interaction of ERRa with nuclear coactivators AIB1, GRIP-1,
or PGC-1a was unaffected by the presence of DMSO, but was
considerably reduced upon treatment with Compound A or the
known ERRa antagonist DES [11,13] (Fig. 3). Upon treatment
with Compound A, AIB1 showed a 35% reduction in comparison
to the vehicle (DMSO) treated sample (Fig. 3A). Similar results
were also seen with nuclear coactivators GRIP-1 (Fig. 3A) or
PGC-1a with either Compound A or DES (Fig. 3B). The nuclear
coactivator PGC-1a exhibited the greatest release with an 81%
reduction (Fig. 3B). The reduction of nuclear coactivator levels
upon treatment with the ERRa antagonist demonstrates disrup-
tion of the constitutive interaction between ERRa and these
coactivators.
To further support the finding that Compound A disrupts the
constitutive interaction between ERRa and nuclear coactivators,
we also performed ChIP assays after MCF-7 cells were treated
with vehicle (DMSO) or 5 uM Compound A for 24 and 48 hours.
The cells were fixed, chromatin was immunoprecipitated with
anti-GRIP-1 antibody, and quantitative real-time PCR (Q-PCR)
was performed with primers targeting well-studied estrogen-
related receptor response elements (ERREs) in ERRa (ESRRA)
[30,31], ACADM (ACADM) [4,32], and pS2 (TFF1) promoters
[6,33]. At 24 hours, treatment with Compound A significantly
decreased association of ERRa/GRIP-1 (P,0.001) (Fig. 3C top)
to a region in ESSRA (ERRa gene), while at 48 hours decreased
association events of ERRa/GRIP-1 to genomic regions flanking
ESSRA, ACADM, and TFF1 (DMSO vs. Cmpd A, P,0.001)
(Fig. 3C bottom) were detected.
Figure 1. ERRa antagonist Compound A inhibits constitutive
transcriptional activity of ERRa. (A) Plasmids pGL2 Luc ERE (empty
vector control) or p3xERE-TK-LUC and phRL-TK renilla plasmid were co-
transfected into MCF-7 cells. After indicated cell treatment, cells were
harvested and cell lysates were assayed for luciferase activity (renilla
normalized). Cells transfected with the p3xERE-TK-Luc showed consti-
tutive activity compared to the empty vector pGL2 Luc treated with
vehicle. MCF-7 cells transfected with the p3xERE-TK-Luc and treated
with E2 conferred a 6.3-fold increase in transcriptional activity while
cells treated with Compound A are significantly repressed, 0.73-fold (or
27% decrease) below basal level (*, P=0.032) (Fig. 1A inset) or when
treated with Compound A in combination with E2, Compound A still
represses the transcriptional effect conferred by ERRa. ICI - 182,780 also
greatly reduces any transactivation. (B) The same experiment (described
above) was performed along with either pcDNA 3.1 (empty vector
control) or pcDNA3.1 hERRa as indicated. Over-expressing ERRa in MCF-
7 cells increases down modulation (relative luciferase activity) within all
treatment groups. Cells transfected with the p3xERE-TK-Luc+pcDNA 3.1
hERRa conferred an 114-fold increase in transcriptional activity above
cells transfected with pGL2 Luc and treated with vehicle. Cells
transfected with the p3xERE-TK-Luc+pcDNA 3.1 hERRa and treated
with E2 exhibited a 2.6-fold increase in transcriptional activity in
comparison to pGL2 Luc+pcDNA3.1 hERRa. Over expressing ERRa leads
to a 45% decrease in transactivation upon treatment with Compound A
(P=0.001) (Fig. 1B inset). Similarly, Cmpd A+E2 led to a 33% decrease
and over expressing ERRa in MCF-7 cells still led to nearly abolishing
transactivation upon treatment with ICI 182,780. Results are expressed
as the normalized luciferase activity (mean6SEM) of three independent
experiments performed in triplicate. Differences in luciferase activity
between vehicle (DMSO) and Cmpd A were measured by ANOVA
followed by a student t-test with a 0.05 significance level. *, P=0.032
and **, P=0.001.
doi:10.1371/journal.pone.0005624.g001
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It has been well established that different ER ligands have
different effects on ERa protein stability and degradation. For
example, at 48 hours 4-hydroxytamoxifen (4-OHT) or idoxifene
increases ERa protein levels, estradiol (E2) or ICI -182,780
induces protein degradation, while others like raloxifene display
little effect [34,35]. Also, given that ERa in some contexts is most
likely needed for ERRa activation to occur (Fig. 1), we examined
the expression status of ERRa after MCF-7 cells were treated with
vehicle (DMSO) or the selective estrogen receptor modulators
(SERMs) 10 nM E2, 10 nM 4-OHT, and 10 nM ICI-182,780 for
24 and 48 hours. Vehicle (DMSO) does not effect protein stability,
while as previously reported [35] E2 or ICI-182,780 leads to
degradation while 4-OHT leads to an increase in ERa (Fig. 4A
top). Interestingly, 4-OHT and ICI-182,780 treated MCF-7 cells
do not alter ERRa levels, while there is a 30% increase in ERRa
after 48 hour treatment with E2 (Fig. 4A bottom). To study the
effects of ERRa and ERa stability after treatment with the ERRa
Figure 2. Compound A treatment effects on mRNA levels of ERRa target genes. MCF-7 breast cancer cells were treated with Compound A for
either24or 48 hours.NochangeinERRa orERa mRNAlevelswere measuredafter24and48 hoursoftreatmentwith the ERRa antagonistversesvehicle
(DMSO), while other ERRa target genes medium-chain acyl coenzyme (ACADM), aromatase (CYP19A1), pyruvate dehydrogenase kinase 4 (PDK4),
osteopontin (SPP1), and pS2 (TFF1) were all significantly (P,0.001) down modulated upon treatment with ERRa antagonist at 24 and/or 48 hours.
Additionally, peroxisome proliferator-activated receptor coactivator-1a (PGC-1a)( PPARGC1A), is also significantly (P,0.001) down modulated upon
treatment with Compound A. These results are representative of three independent experiments performed in triplicate. Differences in relative mRNA
expression between vehicle (DMSO) and Cmpd A were measured by ANOVA followed by a student t-test with a 0.05 significance level.
doi:10.1371/journal.pone.0005624.g002
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(DMSO) or 5 uM Compound A for 12, 24, and 48 hours. Nuclear
extracts were isolated and ERRa and ERa protein levels were
analyzed by Western blot. After a 12 hour incubation with
Compound A, a 20% reduction of ERRa protein was seen
(compare lanes 3 and 4, Fig. 4B); while after 24 hours a 27%
reduction (compare lanes 5 and 6) and after 48 hours a 74%
reduction (compare lanes 7 and 8) of ERRa was detected.
Treating cells with the ERRa antagonist for 12, 24, or 48 hours
yielded negligible ERa protein level changes (Fig. 4B).
To determine whether down regulation of the ERRa protein is
mediated by the ubiquitin proteasome pathway, we treated MCF-
7 cells with vehicle (DMSO), 5 uM Compound A, the proteasome
inhibitor MG132 (1 uM), or 5 uM Compound A plus 1 uM
MG132 for 36 hours. Whole cell extracts were isolated and ERRa
protein levels were analyzed by Western blot. Cells treated with
the ERRa antagonist (lane 3, Fig. 4C) exhibited a 51% reduction
in comparison to vehicle (lane 2). Addition of MG132 slightly
reduced ERRa (lane 4 compared to lane 2) while addition of
MG132 blocks ERRa degradation caused by Compound A (lane 5
compared to lanes 2, 3, and 4) (Fig. 4C). Thus, our results suggest
that Compound A down-regulation of ERRa involves ubiquitin-
mediated proteolysis.
Treatment with the ERRa Antagonist Decreased
Association between ERRa and ERRa Targeted Promoters
In order to investigate the effect of Compound A on ERRa
binding at the promoter region of ERRa target genes (ESRRA,
ACADM, and TFF1), chromatin Immunoprecipitation (ChIP)
assays were performed after MCF-7 cells were treated with
DMSO, 3 pM 17b-estradiol (E2), or 5 uM Compound A for 24
and 48 hours. The cells were fixed, chromatin was immunopre-
cipitated with anti-ERRa antibody, and quantitative real-time
PCR (Q-PCR) was performed with primers targeting well
characterized estrogen-related receptor response elements
(ERREs) in ERRa (ESRRA) [30,31], ACADM [4,32], and pS2
(TFF1) promoters [6,33]. At 24 hours, treatment with Compound
A had little or no effect on ERRa association with these target
genes (Fig. 5A), while at 48 hours decreased association of ESRRA,
ACADM,o rTFF1 (P,0.001) (Fig. 5B) was demonstrated,
Figure 3. Constitutive interaction of ERRa and nuclear coacti-
vators is reduced upon treatment with ERRa antagonist.
Biotinylated pull-down assays with nuclear coactivators AIB1, GRIP-1
(Fig. 3A), and PGC-1a (Fig. 3B). Lane 1 molecular weight ladder. Lane 2,
10% input, in vitro translated full-length human ERRa
35S labeled
protein. Lane 3, sulfo-NHS-LC-biotin plus
35S-labeled ERRa.( A )
Treatment with Compound A; AIB1 RID/ERRa interaction showed a
35% reduction in comparison to the vehicle (DMSO) treated sample
(lane 4 and 5), GRIP-1 RID/ERRa interaction was reduced by 29% (lane 6
and 7). Similarly, AIB1 RID/ERRa interaction showed a 36% reduction in
comparison to the vehicle (DMSO) when treated with DES (lane 8 and
9). (B) Treatment with Compound A; PGC-1a RID/ERRa interaction
exhibited a 81% reduction in comparison to the vehicle (DMSO) treated
sample (lane 4 and 5). Additionally, PGC-1a RID/ERRa interaction
displayed a 37% reduction in comparison to the vehicle (DMSO) when
treated with DES (lane 4 and 6). Pull-down assays represent three
independent experiments yielding similar results. (C) MCF-7 cells
treated with vehicle (DMSO) or Compound A for 24 and 48 hours.
Chromatin was immunoprecipitated with anti-GRIP-1 antibody, and
quantitative real-time PCR (Q-PCR) was performed with primers
targeting estrogen-related receptor response elements (ERREs) in ERRa
(ESRRA), ACADM,a n dp S 2( TFF1). At 24 hours, treatment with
Compound A significantly decreased binding of GRIP-1/ERRa (ESRRA)
(DMSO vs. Cmpd A, P,0.001), while at 48 hours significantly decreased
binding of ERRa (ESRRA), ACADM (ACADM), and pS2 (TFF1)/GRIP-1
(DMSO vs. Cmpd A, P,0.001) was exhibited. All ChIP experiments were
independently repeated yielding reproducible results. Differences in
binding between vehicle (DMSO) and Cmpd A were measured by
ANOVA followed by a student t-test with a 0.05 significance level.
doi:10.1371/journal.pone.0005624.g003
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PLoS ONE | www.plosone.org 7 May 2009 | Volume 4 | Issue 5 | e5624Figure 4. Selective estrogen regulated modulators (SERMs) alter ERa protein stability but have little effect on ERRa. (A) MCF-7 cells
were treated with vehicle (DMSO), E2, 4-OHT, and ICI-182,780 for 24 and 48 hours. ERa and ERRa protein levels (nuclear extracts) were analyzed by
Western blot. Vehicle does not effect ERa protein stability, E2 and ICI-182,780 lead to degradation, and 4-OHT increases ERa stability (Fig. 4A top).
Neither 4-OHT or ICI-182,780 treated cells altered ERRa levels at 24 or 48 hours, while there is a 30% increase in ERRa after 48 hour treatment with E2
(Fig. 4A bottom). (B) MCF-7 cells were treated with vehicle (DMSO) or Compound A for 12, 24, and 48 hours. ERRa and ERa protein levels (nuclear
extracts) were analyzed by Western blot. After a 12 hour incubation with Compound A, a 20% reduction of ERRa protein was seen; while after
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targeted promoters.
Silencing of ERRa Decreases mRNA levels of ERRa Target
Genes but not ERa
Doesreductionof ERRa expression lead to similar effects seen by
antagonizing/down-regulating ERRa with Compound A? Four
different (1–4) plasmids (SuperArray Bioscience Corporation)
expressing short hairpin RNAs (shRNA) specific for ERRa under
the control of the U1 promoter and containing the GFP marker
gene were transfected separately into MCF-7 cells. Additionally, an
shRNA expressing a scrambled artificial sequence that does not
match any human, mouse or rat gene was transfected and used as
the negative control. MCF-7/shRNA ERRa3 cells underwent four
roundsoffluorescent activatedcellsorting (FACS)toenrichforGFP
expressing cells (Fig. 6A). Similar results were seen with MCF-7/
shRNA ERRa2 (data not shown). ERRa mRNA expression was
measured (Fig. 6B-top panel, S2) and as a higher number of GFP
expressing cellswere sortedandisolated (roundsI–IV), a decrease in
ERRa mRNA levels were detected. While only 51% reduction of
ERRa (versus the negative control) was measured with cells that
underwent two rounds of FACS, after 4 rounds the enriched
population exhibited a statistically significant (P,0.05) 79% knock-
down. Similar results were seen with MCF-7/shRNA ERRa2 (data
not shown). Along with ERRa, ACADM and PGC-1a mRNA
expression levels were also determined and statistically significant
(P,0.05) reduction of ACADM and PGC-1a was measured in both
after 4 rounds of FACS (Fig. 6B, S2). ERRa protein expression was
measured (Fig. 6C) and MCF-7/shRNA ERRa3 cells exhibited
69% less protein versus the negative control, while MCF-7/shRNA
ERRa2E R R a protein levels were reduced by 59%. Similarly to
when MCF-7 cells were treated with Compound A (Fig. 2)
knocking-down ERRa by shRNA led to significant decreases
(P,0.05) in expression of ERRa target genes aromatase (CYP19A1),
osteopontin (SPP1), and pS2 (TFF1) while ERa (ESR1) levels were
not affected (Fig. 6D, S3).
Discussion
Breast cancer therapies continue to be an unmet medical need
as an estimated 40,930 (40,480 woman and 450 men) breast
cancer deaths are expected in 2008 [36]. There is growing
evidence that the orphan nuclear receptor ERRa takes part in
breast cancer progression and could be a novel drug target to treat
breast cancer [2,3,21,25,37,38,39]. N-[(2Z)-3-(4,5-dihydro-1,3-
thiazol-2-yl)-1,3-thiazolidin-2-yl idene]-5H dibenzo[a,d][7]annu-
len-5-amine, Compound A, is a recently reported ERRa-subtype
specific ligand, identified on the basis of disrupting the constitutive
interaction between ERRa and nuclear coactivators [21]. In this
study, we characterized the molecular mechanism of Compound
A in modulating ERRa activity.
First, Compound A inhibits the constitutive transcriptional
activity of both endogenous and ectopically expressed ERRa
(Fig. 1A). When ERRa was overexpressed in MCF-7 cells, a greater
window of repression by Compound A was exhibited, and the
overall estrogen responsiveness (measured by an ERE reporter
construct) was down-modulated (Fig. 1B) – an interesting event first
reported by Kraus and colleagues [26]. Our previous research
reports that Compound A specifically binds ERRa [21]. Com-
pound A did not exert a direct effect on ERa either by modulating
mRNA expression or altering protein stability. Furthermore, while
Compound A does not modulate ERRa mRNA expression, it
inducesproteasome-dependentERRaproteindegradation(Fig.2&
4C). Lanvin and colleagues recently reported the ERRa inverse
agonist XCT790 does not act on ERa or ERRa mRNA level, nor
does it modify ERa protein stability, but it also induces proteasome
Figure 5. Treatment with Compound A decreases the associ-
ation of ERRa to ERRa target gene promoters. MCF-7 cells were
treated with DMSO, E2, or Compound A for 24 and 48 hours followed
by ChIP with anti-ERRa antibody. Quantitative real-time PCR (Q-PCR)
was performed with primers targeting estrogen-related receptor
response elements (ERREs) in ERRa (ESRRA), ACADM, and pS2 (TFF1).
(A) At 24 hours, treatment with Compound A had little or no effect on
ERRa binding of target genes ERRa (ESRRA), ACADM, and pS2 (TFF1). (B)
At 48 hours significant decreased binding of ERRa (ESRRA), ACADM, and
pS2 (TFF1)( P ,0.001) was exhibited. All ChIP experiments were
independently replicated in triplicate. Differences in binding between
vehicle (DMSO) and Cmpd A were measured by ANOVA followed by a
student t-test with a 0.05 significance level.
doi:10.1371/journal.pone.0005624.g005
24 hours a 27% reduction and after 48 hours a 74% reduction of ERRa was exhibited. Additionally, treating cells with ERRa antagonist for 12, 24, or
48 hours yielded negligible ERa protein level changes (Fig. 4B bottom). (C) MCF-7 cells were treated with vehicle (DMSO), Compound A, MG132, or
Compound A plus MG132 for 36 hours. ERRa protein levels (whole cell extracts) were analyzed by Western blot. Cells treated with Compound A
exhibited a 51% reduction in comparison to vehicle. Addition of MG132 blocks ERRa degradation caused by Compound A. Equal loading of nuclear
protein extracts per lane was assessed by Coomassie blue staining of gels (Fig. 4A,B) while additionally; equal loading of whole cell protein extracts
per lane was assessed by stripping the nitrocellulose membrane and re-probing with b-actin monoclonal antibody (Fig. 4C). Densitometric
quantification of protein levels is described in Materials and Methods. All Western blots included human full-length ERa and/or ERRa in vitro translated
proteins which were used as positive controls. Results shown are representative of three independent experiments.
doi:10.1371/journal.pone.0005624.g004
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PLoS ONE | www.plosone.org 9 May 2009 | Volume 4 | Issue 5 | e5624Figure 6. Knock-down of ERRa by shRNA (RNAi) decreases mRNA levels of multiple ERRa target genes. Short hairpin plasmids
expressing short hairpin RNA (shRNA) specific for knocking-down ERRa were transfected separately into MCF-7 cells. In addition, a shRNA expressing
a scrambled artificial non-specific sequence was transfected. (-) control. (A) MCF-7/shRNA ERRa3 cells underwent four rounds (I–IV) of fluorescent
activated cell sorting (FACS) to enrich for GFP expressing cells. FACS is described in Materials and Methods. (B) ERRa (ESRRA), ACADM, and PGC-1a
(PPARGC1A) mRNA expression was measured by real-time RT-PCR. After 4 rounds of FACS, MCF-7/shRNA ERRa3 cells ERRa (ESRRA) mRNA levels were
significantly reduced by 79%, ACADM levels by 75%, and PGC-1a (PPARGC1A) by 71% (*, P,0.05). Differences in relative mRNA expression between
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MCF-7 cells were treated with Compound A for 12 hours and
24 hours, modest 20% and 27% reduction in protein levels are seen
(Fig. 4B). But at 48 hours, a robust 74% reduction was observed.
When MCF-7 cells were treated with Compound A for 48 hours,
followed by ChIP performed with anti-ERRa antibody there was a
significant decreased association to the three promoters (ESRRA,
ACADM, and TFF1) (Fig. 5B). Therefore, based on our ERRa ChIP
(Fig. 5B) and our Western blot data (Fig. 4B, C), the decrease in
association of ERRa at the promoter region of ERRa target genes,
is most likely due to protein degradation of ERRa caused by
Compound A.
It has been previously demonstrated that the ERR antagonist
DES interferes with the constitutive interaction between ERRc
and the nuclear coactivator GRIP-1 [13]. Therefore, to investigate
whether or not Compound A could antagonize the constitutive
interaction between ERRa and nuclear coactivators we performed
biotinylated pull-down assays with AIB1, GRIP-1, and PGC-1a
nuclear coactivators. Our data suggest that Compound A
promotes nuclear coactivator release between the ERRa and
AIB1, GRIP-1, or PGC-1a (Fig. 3A,B).
To extend the finding that Compound A is acting like an
antagonist and disrupts the constitutive interaction between ERRa
and nuclear coactivators, ChIP assays were carried out after MCF-
7 cells were treated with vehicle or Compound A. At 24 hours, a
significant decrease in the interaction between GRIP-1/and
ERRa (DMSO vs. Compound A, P,0.001) (Fig. 3C top) was
exhibited. In comparison, when MCF-7 cells were treated with the
ERRa antagonist for 24 hours, only a 27% reduction in ERRa
protein levels were seen (Fig. 4B). Thus the ability of Compound A
to directly interfere with cofactor association is demonstrated by
ChIP. At 48 hours, decreased binding of ERRa (ESRRA),
ACADM, and pS2 (TFF1)/GRIP-1 (DMSO vs. Cmpd A,
P,0.001) (Fig. 3C bottom) was demonstrated and at 48 hours, a
robust 74% reduction is reported (Fig. 4B). Therefore, at 48 hours,
the significant (DMSO vs. Compound A, P,0.001) decrease in
association between GRIP-1 and ERRa target genes is most likely
due to degradation of ERRa protein.
In order to confirm that antagonizing/down-modulating of
ERRa by Compound A is specifically acting through ERRa,w e
used shRNA plasmids to knock-down endogenous ERRa. After
four rounds of FACS, excluding ERa (ESR1), all other genes were
significantly reduced (P,0.05) in MCF-7/shRNA ERRa3 cells
(Fig. 6B), corroborating the effects seen when MCF-7 cells were
treated with the ERRa-subtype specific ligand, Compound A, for
24 hours (Fig. 2). Furthermore, treatment of MCF-7 breast cancer
cells with Compound A, leads to inhibition of growth; similarly,
MCF-7/shRNA ERRa3 cell growth is also slowed when
compared to the control MCF-7/shRNA (-) cell line [39].
It has been well demonstrated that targeting ERa with such
drugs as tamoxifen and ICI-182,780 (faslodex) has lead to
successful therapy [40,41]. Therefore, future studies should
include treating ERa (+) cells with combinations of tamoxifen,
faslodex or an aromatase inhibitor with Compound A. Addition-
ally, it would be of great interest to treat both ERa (-) and
tamoxifen resistant cells with Compound A. In the future it will be
interesting to study the effects of knocking-down or antagonizing
both ERa and ERRa in breast cancer cells. Intriguingly, Lanvin
and coauthors recently reported that the XCT790, an ERRa
selective inverse agonist, plus the pure anti-estrogen ICI-182,780
potentiates the ICI-182,780 induced ERa degradation inferring
XCT790 may enhance the efficacy of ICI-182,780 in breast
cancer treatment. Additionally, XCT790+ICI-182,780 dramati-
cally enhanced ERRa degradation verses ERRa degradation
induced by just XCT790 [23].
Based on supporting data in the literature an ERRa specific
antagonist shows exciting potential as a novel therapy to treat
breast cancer. ERRa is expressed in numerous human breast
cancer cell lines, breast tumors, and in breast adipose tissue
[6,37,38]. ERRa expression in human breast carcinomas is
significantly associated with an increased risk of disease recurrence
or poor clinical outcome [38]. It has been reported that ERRa
expression is associated with an adverse, aggressive tumor
phenotype correlating with ERBB2 (HER2, NEU) overexpression
[37]. Additionally, the ERRa ligand DES slows breast cancer cell
growth at high concentrations (in vitro) [6] and in the past has been
used to treat breast cancer in clinical settings [42]. ERRa
antagonists may also be used for ER-negative cancers. BT-20/
shRNA ERRa knock-down cell lines were also established and
sorted by FACS. Interestingly, after the second round of GFP
enrichment, BT-20 (ER-negative) [43] cells carrying shRNA
ERRa plasmid, stopped growing (data not shown).
The possibility of an ERRa antagonist to treat breast cancer plus
our recent discovery of new ERRa-subtype specific ligands has led
to an effort to characterize the mechanisms of action of ERRa
specific antagonists. In particular, N-[(2Z)-3-(4,5-dihydro-1,3-thia-
zol-2-yl)-1,3-thiazolidin-2-yl idene]-5H dibenzo[a,d][7]annulen-5-
amine, (termed Compound A) which has the strongest antagonistic
effect on the constitutive interaction between ERRa and nuclear
coactivators among the ligands we identified [21]. The pure anti-
estrogen ICI, 182,780, which is presently being used to successfully
treat breast cancer in the clinic [44] has little effect on ERa mRNA
levels [35], promotes cofactor disassociation [45], and induces ERa
protein proteasome mediated degradation [35,46]. Similarly, we
have shown that Compound A has little effect on ERRa (and ERa)
mRNA levels (Fig. 2), promotes cofactor disassociation (Fig. 3), and
induces ERRa protein proteasome mediated degradation (Fig. 4).
We report Compound A inhibits ERRa transcriptional activity in
MCF-7 cells, and ERRa target genes such as pS2 (TFF1),
osteopontin (SPP1), and aromatase (CYP19A1) mRNA levels
decreased upon treatment with the ERRa ligand. Knocking-down
ERRa (by shRNA) led to similar genomic effects seen when MCF-7
cells were treated with our ERRa antagonist; thereby confirming
Compound A’s target as ERRa. Our studies presented here
improve our understanding of the mechanism of action of the
ERRa specific antagonist, Compound A.
MCF-7/shRNA (-) and MCF-7/shRNA ERRa3 were measured by ANOVA followed by a student t-test with a 0.05 significance level. (C) MCF-7, MCF-7/
shRNA (-), MCF-7/shRNA ERRa2, and MCF-7/shRNA ERRa3 cells ERRa protein expression was measured by Western blot, equal loading of protein was
assessed by Coomassie blue staining of gels, and densitometric quantification are described in Materials and Methods. Results shown are
representative of three independent experiments. MCF-7/shRNA ERRa2 exhibited 59% less protein verses the negative control, while MCF-7/shRNA
ERRa3 cells ERRa protein levels were reduced by 69%. (D) ERa (ESR1), aromatase (CYP19A1), osteopontin (SPP1), and pS2 (TFF1) mRNA expression was
measured in MCF-7/shRNA (-), MCF-7/shRNA ERRa2, and MCF-7/shRNA ERRa3 cells by real-time RT-PCR after 4 rounds of FACS. Knocking-down ERRa
by shRNA (RNAi) led to significant decrease (*, P,0.05) in expression of ERRa target genes aromatase (CYP19A1), osteopontin (SPP1), and pS2 (TFF1)
while ERa (ESR1) levels were not affected. All real-time RT-PCR results are representative of three independent experiments performed in triplicate.
doi:10.1371/journal.pone.0005624.g006
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Figure S1 Mean delta CT values that correspond to the relative
gene expression displayed in Figure 2. See Materials and Methods
(Real-time RT-PCR) for more information on mean delta CT
values.
Found at: doi:10.1371/journal.pone.0005624.s001 (0.06 MB TIF)
Figure S2 Mean delta CT values that correspond to the relative
gene expression displayed in Figure 6B.
Found at: doi:10.1371/journal.pone.0005624.s002 (0.01 MB TIF)
Figure S3 Mean delta CT values that correspond to the relative
gene expression displayed in Figure 6D.
Found at: doi:10.1371/journal.pone.0005624.s003 (0.01 MB TIF)
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